Obinutuzumab in systemic lupus erythematosus: a real-world experience.

ABSTRACT:

Objectives

To describe the real-world efficacy and safety of obinutuzumab in a heterogeneous systemic lupus erythematosus (SLE) population, including severe or refractory manifestations.

Methods

We retrospectively analyzed 56 SLE patients who received a single dose of obinutuzumab (1000 mg) at Renji Hospital, Shanghai Jiao Tong University School of Medicine between October 2021 and March 2024. Patients were followed for 48 weeks. Outcomes included the proportion of patients achieving definitions of remission in systemic lupus erythematosus (DORIS), Lupus Low Disease Activity State (LLDAS), clinical stable, and flare. Changes in SLEDAI-2K, anti-dsDNA, complement levels, B cell counts, glucocorticoid dose, and adverse events were assessed. Subgroup analyses were performed to a

SUBMITTER: Wu C 

PROVIDER: S-EPMC12672876 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature